Gamida Cell Ltd. has declared that the initial patient has been subjected to a stem cell transplantation procedure using Omisirge (omidubicel-onlv).

This article summarized the latest R&D progress of Gliclazide, the Mechanism of Action for Gliclazide, and the drug target R&D trends for Gliclazide.

Abeona Therapeutics Inc. has reported that they've lodged a BLA with U.S. FDA with a request to endorse EB-101.

This article summarized the latest R&D progress of Fosfomycin tromethamine, the Mechanism of Action for Fosfomycin tromethamine, and the drug target R&D trends for Fosfomycin tromethamine.

The US FDA approved AltruBio Inc.'s IND request, allowing Phase 2 clinical trials to start for its immune checkpoint booster, ALTB-268, for ulcerative colitis.

This article summarized the latest R&D progress of Lanthanum carbonate, the Mechanism of Action for Lanthanum carbonate, and the drug target R&D trends for Lanthanum carbonate.

Intercept's principal drug is Ocaliva® (obeticholic acid), an FDA-approved farnesoid X receptor agonist in the United States and numerous other regions.

This article summarized the latest R&D progress of Flutamide, the Mechanism of Action for Flutamide, and the drug target R&D trends for Flutamide.

Gracell Biotechnologies Inc. has announced that the initial patient in the US has begun treatment in a Phase 1b/2 clinical trial for it's foremost candidate, GC012F, targeting patients with recurrent or resistant multiple myeloma.

This article summarized the latest R&D progress of Flunisolide, the Mechanism of Action for Flunisolide, and the drug target R&D trends for Flunisolide.

Adverum Biotechnologies has released early findings on aflibercept protein activity from its ongoing Phase 2 LUNA study.

This article summarized the latest R&D progress of Fenofibric acid, the Mechanism of Action for Fenofibric acid, and the drug target R&D trends for Fenofibric acid.